Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benzethonium Chloride Review Prior To Final Monograph Urged By Lonza

This article was originally published in The Tan Sheet

Executive Summary

A safety review of benzethonium chloride as a Category I active ingredient in the healthcare antiseptic products monograph should be conducted by FDA before completing the rule, chemical ingredient supplier Lonza suggests.

You may also be interested in...



Benzethonium Chloride Finished Formula Data Support Antiseptic Use – Lonza

Safety and efficacy studies on the use of benzethonium chloride in finished-product formulas bear out a Category I classification in the healthcare antiseptic monograph, chemical ingredient supplier Lonza says in a May 15 citizen petition to FDA

Benzethonium Chloride Finished Formula Data Support Antiseptic Use – Lonza

Safety and efficacy studies on the use of benzethonium chloride in finished-product formulas bear out a Category I classification in the healthcare antiseptic monograph, chemical ingredient supplier Lonza says in a May 15 citizen petition to FDA

Benzethonium Chloride Finished Formula Data Support Antiseptic Use – Lonza

Safety and efficacy studies on the use of benzethonium chloride in finished-product formulas bear out a Category I classification in the healthcare antiseptic monograph, chemical ingredient supplier Lonza says in a May 15 citizen petition to FDA

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel